Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional Study
Background This study aimed to identify the clinical characteristics of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) in the Republic of Korea. Methods Data of notified people with tuberculosis between July 2018 and December 2021 were retrieved from the Korea Tuberculosis Cohort...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2025-01-01
|
| Series: | Tuberculosis and Respiratory Diseases |
| Subjects: | |
| Online Access: | http://e-trd.org/upload/pdf/trd-2024-0049.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850153378788671488 |
|---|---|
| author | Jinsoo Min Yousang Ko Hyung Woo Kim Hyeon-Kyoung Koo Jee Youn Oh Doosoo Jeon Taehoon Lee Young-Chul Kim Sung Chul Lim Sung Soon Lee Jae Seuk Park Ju Sang Kim |
| author_facet | Jinsoo Min Yousang Ko Hyung Woo Kim Hyeon-Kyoung Koo Jee Youn Oh Doosoo Jeon Taehoon Lee Young-Chul Kim Sung Chul Lim Sung Soon Lee Jae Seuk Park Ju Sang Kim |
| author_sort | Jinsoo Min |
| collection | DOAJ |
| description | Background This study aimed to identify the clinical characteristics of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) in the Republic of Korea. Methods Data of notified people with tuberculosis between July 2018 and December 2021 were retrieved from the Korea Tuberculosis Cohort database. MDR/RR-TB was further categorized according to isoniazid susceptibility as follows: multidrug-resistant tuberculosis (MDR-TB), rifampicin-monoresistant tuberculosis (RMR-TB), and RR-TB if susceptibility to isoniazid was unknown. Multivariable logistic regression analysis was conducted to identify the factors associated with MDR/RR-TB. Results Between 2018 and 2021, the proportion of MDR/RR-TB cases among all TB cases and TB cases with known drug susceptibility test results was 2.1% (502/24,447). The proportions of MDR/RR-TB and MDR-TB cases among TB cases with known drug susceptibility test results were 3.3% (502/15,071) and 1.9% (292/15,071), respectively. Among all cases of rifampicin resistance, 31.7% (159/502) were RMR-TB and 10.2% (51/502) were RR-TB. Multivariable logistic regression analyses revealed that younger age, foreigners, and prior tuberculosis history were significantly associated with MDR/RR-TB. Conclusion Rapid identification of rifampicin resistance targeting the high-risk populations, such as younger generations, foreign-born individuals, and previously treated patients are necessary for patient-centered care. |
| format | Article |
| id | doaj-art-2aec8096c95e49d78f01db9c7f707bb3 |
| institution | OA Journals |
| issn | 1738-3536 2005-6184 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | The Korean Academy of Tuberculosis and Respiratory Diseases |
| record_format | Article |
| series | Tuberculosis and Respiratory Diseases |
| spelling | doaj-art-2aec8096c95e49d78f01db9c7f707bb32025-08-20T02:25:44ZengThe Korean Academy of Tuberculosis and Respiratory DiseasesTuberculosis and Respiratory Diseases1738-35362005-61842025-01-0188115916910.4046/trd.2024.00494895Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional StudyJinsoo Min0Yousang Ko1Hyung Woo Kim2Hyeon-Kyoung Koo3Jee Youn Oh4Doosoo Jeon5Taehoon Lee6Young-Chul Kim7Sung Chul Lim8Sung Soon Lee9Jae Seuk Park10Ju Sang Kim11 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Kangdong Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Republic of Korea Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea Division of Pulmonology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of KoreaBackground This study aimed to identify the clinical characteristics of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) in the Republic of Korea. Methods Data of notified people with tuberculosis between July 2018 and December 2021 were retrieved from the Korea Tuberculosis Cohort database. MDR/RR-TB was further categorized according to isoniazid susceptibility as follows: multidrug-resistant tuberculosis (MDR-TB), rifampicin-monoresistant tuberculosis (RMR-TB), and RR-TB if susceptibility to isoniazid was unknown. Multivariable logistic regression analysis was conducted to identify the factors associated with MDR/RR-TB. Results Between 2018 and 2021, the proportion of MDR/RR-TB cases among all TB cases and TB cases with known drug susceptibility test results was 2.1% (502/24,447). The proportions of MDR/RR-TB and MDR-TB cases among TB cases with known drug susceptibility test results were 3.3% (502/15,071) and 1.9% (292/15,071), respectively. Among all cases of rifampicin resistance, 31.7% (159/502) were RMR-TB and 10.2% (51/502) were RR-TB. Multivariable logistic regression analyses revealed that younger age, foreigners, and prior tuberculosis history were significantly associated with MDR/RR-TB. Conclusion Rapid identification of rifampicin resistance targeting the high-risk populations, such as younger generations, foreign-born individuals, and previously treated patients are necessary for patient-centered care.http://e-trd.org/upload/pdf/trd-2024-0049.pdfrifampicinmultidrug-resistant/rifampicin-resistant tuberculosisprevalence |
| spellingShingle | Jinsoo Min Yousang Ko Hyung Woo Kim Hyeon-Kyoung Koo Jee Youn Oh Doosoo Jeon Taehoon Lee Young-Chul Kim Sung Chul Lim Sung Soon Lee Jae Seuk Park Ju Sang Kim Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional Study Tuberculosis and Respiratory Diseases rifampicin multidrug-resistant/rifampicin-resistant tuberculosis prevalence |
| title | Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional Study |
| title_full | Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional Study |
| title_fullStr | Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional Study |
| title_full_unstemmed | Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional Study |
| title_short | Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional Study |
| title_sort | clinical profiles of multidrug resistant and rifampicin monoresistant tuberculosis in korea 2018 2021 a nationwide cross sectional study |
| topic | rifampicin multidrug-resistant/rifampicin-resistant tuberculosis prevalence |
| url | http://e-trd.org/upload/pdf/trd-2024-0049.pdf |
| work_keys_str_mv | AT jinsoomin clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT yousangko clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT hyungwookim clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT hyeonkyoungkoo clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT jeeyounoh clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT doosoojeon clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT taehoonlee clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT youngchulkim clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT sungchullim clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT sungsoonlee clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT jaeseukpark clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy AT jusangkim clinicalprofilesofmultidrugresistantandrifampicinmonoresistanttuberculosisinkorea20182021anationwidecrosssectionalstudy |